These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31508822)

  • 21. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
    Simpson CB; Lee CT; Hatcher JL; Michalek J
    Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment efficacy of electromyography versus fiberscopy-guided botulinum toxin injection in adductor spasmodic dysphonia patients: a prospective comparative study.
    Kim JW; Park JH; Park KN; Lee SW
    ScientificWorldJournal; 2014; 2014():327928. PubMed ID: 25383369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spasmodic dysphonia: a seven-year audit of dose titration and demographics in the Indian population.
    Nerurkar NK; Banu TP
    J Laryngol Otol; 2014 Jul; 128(7):649-53. PubMed ID: 24999662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current practices in the management of adductor spasmodic dysphonia.
    Eskander A; Fung K; McBride S; Hogikyan N
    J Otolaryngol Head Neck Surg; 2010 Oct; 39(5):622-30. PubMed ID: 20828529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abductor paralysis after botox injection for adductor spasmodic dysphonia.
    Venkatesan NN; Johns MM; Hapner ER; DelGaudio JM
    Laryngoscope; 2010 Jun; 120(6):1177-80. PubMed ID: 20513036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surgery or botulinum toxin for adductor spasmodic dysphonia: a comparative study.
    Mendelsohn AH; Berke GS
    Ann Otol Rhinol Laryngol; 2012 Apr; 121(4):231-8. PubMed ID: 22606926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors influencing long-term treatment response to botulinum toxin injection for spasmodic dysphonia.
    Kang MS; Lee SJ; Choi HS; Lim JY
    Clin Otolaryngol; 2021 Mar; 46(2):436-444. PubMed ID: 33260261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study.
    Cha W; Jang JY; Wang SG; Kang JH; Jo MG
    J Voice; 2017 May; 31(3):378.e19-378.e24. PubMed ID: 27520509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retropharyngeal hematoma following botulinum toxin injection for abductor spasmodic dysphonia.
    Koh J; Raghav S; Baxter M
    Ear Nose Throat J; 2017 Dec; 96(12):E45-E46. PubMed ID: 29236283
    [No Abstract]   [Full Text] [Related]  

  • 30. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes.
    Novakovic D; Waters HH; D'Elia JB; Blitzer A
    Laryngoscope; 2011 Mar; 121(3):606-12. PubMed ID: 21298641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Botulinum Toxin Injections and Type 2 Thyroplasty for Adductor Spasmodic Dysphonia.
    Sanuki T; Takemoto N
    Laryngoscope; 2023 Dec; 133(12):3443-3448. PubMed ID: 37278482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia.
    Holden PK; Vokes DE; Taylor MB; Till JA; Crumley RL
    Ann Otol Rhinol Laryngol; 2007 Dec; 116(12):891-6. PubMed ID: 18217507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment efficacy of electronic endoscope-guided botulinum toxin injection in adductor spasmodic dysphonia patients].
    Ren J; Yang H; Wang H; Zou J; Lv D; Yu L; Zheng Y
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Nov; 34(11):1019-1023. PubMed ID: 33254323
    [No Abstract]   [Full Text] [Related]  

  • 34. Onabotulinum toxin A dosage trends over time for adductor spasmodic dysphonia: A 15-year experience.
    Tang CG; Novakovic D; Mor N; Blitzer A
    Laryngoscope; 2016 Mar; 126(3):678-81. PubMed ID: 26308153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Life Threatening Delayed Complication of Botulinum Toxin Injection for Treatment of Spasmodic Dysphonia.
    Yershov D; Partridge R
    Prague Med Rep; 2020; 121(2):114-117. PubMed ID: 32553095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved vocal quality and decreased vocal effort after botulinum toxin treatment for laryngeal dystonia.
    Leung JS; Rosenbaum A; Holmberg J; Villarroel P; Napolitano C; Badía PI; Lagos-Villaseca A
    Auris Nasus Larynx; 2024 Feb; 51(1):106-112. PubMed ID: 37365040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
    Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Voice analysis in adductor spasmodic dysphonia: Objective diagnosis and response to botulinum toxin.
    Suppa A; Asci F; Saggio G; Marsili L; Casali D; Zarezadeh Z; Ruoppolo G; Berardelli A; Costantini G
    Parkinsonism Relat Disord; 2020 Apr; 73():23-30. PubMed ID: 32222482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botox treatment in adductor spasmodic dysphonia: a meta-analysis.
    Boutsen F; Cannito MP; Taylor M; Bender B
    J Speech Lang Hear Res; 2002 Jun; 45(3):469-81. PubMed ID: 12069000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Botulinum Toxin Therapy for Spasmodic Dysphonia in Japan: The History and an Update.
    Hyodo M; Hirose K; Nagao A; Nakahira M; Kobayashi T
    Toxins (Basel); 2022 Jul; 14(7):. PubMed ID: 35878189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.